-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis…
-
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design expert Nanoform Finland (HEL: NANOFH) for Starmap, an innovative AI-enabled platform. This platform facilitates confidential in silico testing of molecule candidates prior to chemical synthesis, aiming to reduce clinical attrition throughout the drug development pipeline.…
-
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a smart Artificial Intelligence (AI) Q&A bot for its antiviral drug Yueruiling (leritrelvir). This AI-driven platform is designed to enhance patient support by providing smart Q&A services, an offline drug purchase map guide, and a comprehensive…
-
Baidu Launches Interactive AI Medication Instructions Service at Baidu World 2023
•
Robin Li, CEO of China-based internet services giant Baidu, unveiled an innovative interactive AI medication instructions service during the Baidu World 2023 conference earlier this week. This groundbreaking product is the first of its kind in China, designed to utilize the ERNIE GPT bot and Digital Human novel models. The…
-
Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery
•
France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech firm BioMap, an AI-driven drug discovery platform founded by Robin Li, CEO of Chinese internet leader Baidu (NASDAQ: BIDU; HKG: 9888), and Wei Liu, CEO of Baidu Ventures. The collaboration includes an upfront payment of…
-
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
•
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement with US firm Exelixis Inc., (NASDAQ: EXEL), granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1. USP1 has been identified as a synthetic lethal target in the…
-
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
•
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies…
-
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
•
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies…
-
XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership with US cancer therapy developer Parthenon Therapeutics Inc. to develop antibodies targeting solid tumors. This collaboration aims to leverage the power of AI to advance oncology treatments. Access to XtalPi’s XupremAb Platform and “Experiment+AI” SolutionsUnder…
-
XtalPi Inc. Partners with Edelweiss Connect to Revolutionize Skincare Safety Assessment
•
Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership with Edelweiss Connect, a Swiss company specializing in next-generation product design and risk assessment solutions. This collaboration aims to leverage the unique strengths of both companies in chemical and pharmaceutical safety assessment, technology platforms, and market…
-
Beijing Drafts Regulations for Internet Diagnosis and Treatment, Prohibits AI Prescriptions
•
The Beijing Municipal Health Commission has released the “Implementation Measures for Internet Diagnosis and Treatment Supervision in Beijing (Trial)(draft proposal)” and is soliciting public feedback from August 17 to September 16, 2023. This document outlines the supervision of online diagnosis and treatment activities by medical institutions in Beijing, aligning with…
-
CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine Ltd and Shenzhen XtalPi (QuantumPharm, HKG: 2228). These collaborations will integrate artificial intelligence (AI) into the field of innovative drug research and development. Under the agreements, CSPC will utilize its drug R&D expertise alongside the…
-
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
•
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have revealed a setback in late-stage clinical trials for the potential first-in-class trace amine-associated receptor 1 (TAAR1) agonist, ulotaront, as a treatment for schizophrenia. Topline data from the Phase III DIAMOND 1 and DIAMOND 2 studies…
-
Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology
•
Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has entered into a partnership with Shanghai-headquartered medical imaging company United Imaging Healthcare (UIH, SHA: 688271). The collaboration aims to harness the power of advanced medical intelligent technologies to enhance medical services. Integrating AI and Nuclear…
-
MindRank Ltd Secures Over $20 Million in Series A+ Funding to Advance AI Drug Development
•
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20 million in a Series A+ financing round. Cherami Investment led the investment, which will be utilized to enhance drug development efforts and to upgrade and commercialize the company’s AI drug development platform. Upgrading the AI…
-
Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development
•
Wuhan-based Binhui Biopharmaceutical and Hubei Topgene Biotechnology Co., Ltd have announced a strategic partnership to delve into new drug research and development services, technological innovation, AI platforms, and other collaborative fields. This partnership aims to promote complementary advantages, resource sharing, talent exchange, and establish a joint platform to assist in…
-
Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement
•
China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman institute to bolster the research and development of tumor drugs with novel targets. This collaboration aims to leverage Insilico’s generative AI platform and ShanghaiTech’s expertise in structural biology to advance drug discovery. Leveraging AI for…
-
Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare
•
China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate with telecoms giant Huawei Cloud on the construction of a large artificial intelligence (AI) model in the healthcare industry, with the aim of developing and offering smart medical services. Leveraging Expertise for Smart Medical ServicesUnder…
-
XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly & Co., (NYSE: LLY) to provide AI drug discovery services. The deal, valued at up to USD 250 million in total upfront and milestone payments, will involve XtalPi leveraging its AI capabilities and robotics platform to…
-
Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China
•
US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics, in the Chinese market. This collaborative platform aims to connect industry, academia, research, and medicine, leveraging existing orthopedic integration platforms, industry chain capabilities, digitalization, and artificial intelligence technologies. With an open and collaborative approach, Medtronic…
